trevor pickersgill, looking to the future, treatments

34
Looking to the Future: Next 21yrs Dr Trevor Pickersgill Consultant Neurologist University Hospital of Wales Royal Glamorgan Hospital

Upload: ms-trust

Post on 21-Jan-2018

65 views

Category:

Healthcare


2 download

TRANSCRIPT

Page 1: Trevor Pickersgill, looking to the future, treatments

Looking to the Future: Next 21yrs

Dr Trevor Pickersgill

Consultant Neurologist

University Hospital of Wales

Royal Glamorgan Hospital

Page 2: Trevor Pickersgill, looking to the future, treatments

Declarations• Research post 1996-8 - Schering AG ESPMS trial• Travel/Conference hospitality: Biogen-Idec, Merck-Serono, Novartis, Roche,

Sanofi-Genzyme• Advisory Board Remuneration/Honoraria: Biogen-Idec, Teva, Roche,

MedDay, Novartis, Merck-Serono• Educational Grants: GSK, Teva, UCB • Director & Trustee: Association of British Neurologists; Hospital Medical

Staffs Defence Trust• Council Member: ABN, BMA

Page 3: Trevor Pickersgill, looking to the future, treatments
Page 4: Trevor Pickersgill, looking to the future, treatments

What do we want?

• Technology....?• Crystal ball• Drugs drugs drugs

• Anti-inflammatory• Restorative/remyelinative• protective

• ‘cure’.....

Page 5: Trevor Pickersgill, looking to the future, treatments

RM dob 1987….inflammation in 2005(18)

Page 6: Trevor Pickersgill, looking to the future, treatments

….atrophy 2012….

Page 7: Trevor Pickersgill, looking to the future, treatments
Page 8: Trevor Pickersgill, looking to the future, treatments

• Fig 2. Comparison of the survival in MS patients with the survival of the French general population.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, et al. (2015) Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. PLOS ONE 10(7): e0132033. https://doi.org/10.1371/journal.pone.0132033http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0132033

Page 9: Trevor Pickersgill, looking to the future, treatments

Kaplan-Meier survival curves of patients with multiple sclerosis (MS) in Hordaland county from birth (left column: A, C, E, G) and from disease onset (right column: B, D, F, H).

Hanne-Marie Bøe Lunde et al. J Neurol Neurosurg Psychiatry doi:10.1136/jnnp-2016-315238©2017 by BMJ Publishing Group Ltd

Page 10: Trevor Pickersgill, looking to the future, treatments

What can we do to stop PWMS dying and getting disabled?

Page 11: Trevor Pickersgill, looking to the future, treatments

More better drugs...?

• “me-too” xxxxxxxxx-mabs• New kids in a crowded market

• Need to be game changing (easy....oral....)• Or cheap.....• Or risk-free......

• Identifying new immune targets• Leads to more and unexpected problems..?

Page 12: Trevor Pickersgill, looking to the future, treatments

Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Cochrane Database of Systematic Reviews25 APR 2017 DOI: 10.1002/14651858.CD012200.pub2http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012200.pub2/full#CD012200-fig-0007

Page 13: Trevor Pickersgill, looking to the future, treatments
Page 14: Trevor Pickersgill, looking to the future, treatments

Organised inpatient (stroke unit) care for stroke

Cochrane Database of Systematic Reviews11 SEP 2013 DOI: 10.1002/14651858.CD000197.pub3http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000197.pub3/full#CD000197-fig-00109

Page 15: Trevor Pickersgill, looking to the future, treatments

Odds of death occurring by end of scheduled follow up in stroke unit compared with conventional care.

British Medical Journal Publishing Group BMJ 1997;314:1151©1997 by British Medical Journal Publishing Group

Page 16: Trevor Pickersgill, looking to the future, treatments

Odds ratio (95% confidence interval) of death or requiring institutional care at the end of scheduled follow up in patients receiving stroke unit compared with conventional care.

British Medical Journal Publishing Group BMJ 1997;314:1151©1997 by British Medical Journal Publishing Group

Page 17: Trevor Pickersgill, looking to the future, treatments

• HASU......

• HANU.....HABU...?

• Regional Units 8 beds...?

• Does it really add up?

Page 18: Trevor Pickersgill, looking to the future, treatments

What about prevention?

Page 19: Trevor Pickersgill, looking to the future, treatments
Page 20: Trevor Pickersgill, looking to the future, treatments
Page 21: Trevor Pickersgill, looking to the future, treatments

Cox proportional hazard regression graph showing survival from birth (A) by lifelong smoking status and (B) latest smoking status.

Page 22: Trevor Pickersgill, looking to the future, treatments
Page 23: Trevor Pickersgill, looking to the future, treatments

Improving Disability?

Page 24: Trevor Pickersgill, looking to the future, treatments
Page 25: Trevor Pickersgill, looking to the future, treatments

Estimates of differences between treatments:

Highly significant difference between treatments, but not periods.

TreatmentEffect

Estimateddifference

95% CI

Hospital - None 1.4 0.62, 2.14

Home - None 1.5 0.73, 2.26

Home - Hospital 0.1 -0.65, 0.87

Page 26: Trevor Pickersgill, looking to the future, treatments
Page 27: Trevor Pickersgill, looking to the future, treatments
Page 28: Trevor Pickersgill, looking to the future, treatments

Neuroprotection: Atrophy

Page 29: Trevor Pickersgill, looking to the future, treatments
Page 30: Trevor Pickersgill, looking to the future, treatments
Page 31: Trevor Pickersgill, looking to the future, treatments
Page 32: Trevor Pickersgill, looking to the future, treatments
Page 33: Trevor Pickersgill, looking to the future, treatments

What about the biology...

• More PMs• More pathology research/brain bank• More risk factors• Smoking• Vit D• Infection• Genes

• Biomarkers....Bioprediction• Neurofilament NFL - CSF (serum)• Genetic array

Page 34: Trevor Pickersgill, looking to the future, treatments

And more trials in Progressive MS!!